Новости
хирургии
Журнал включен
в систему цитирования Scopus





2009 г. №1 Том 17

ЛЕКЦИИ, ОБЗОРЫ

Р.Э. ЯКУБЦЕВИЧ, В.В. СПАС, П.П. ПРОТАСЕВИЧ

АHТИКОАГУЛЯHТHАЯ ТЕРАПИЯ ПРИ ПРОВЕДЕHИИ ЭКСТРАКОРПОРАЛЬHОЙ ДЕТОКСИКАЦИИ В ИHТЕHСИВHОЙ ТЕРАПИИ

УОЗ «Гродненская областная клиническая больница»,
УО «Гродненский государственный медицинский университет»,
Республика Беларусь

Важными технологиями лечения критических состояний в интенсивной терапии являются методы экстракорпоральной детоксикации (гемосорбция, гемодиализ, плазмаферез, гемофильтрация и другие). Известно, что при проведении этих процедур для профилактики тромбоза экстракорпорального контура следует применять те или иные антикоагулянты. Разнообразие средств, методов и способов антикоагулянтной терапии на сегодняшний день заставляет специалистов, которые проводят данные виды лечения, выбрать наиболее эффективный и безопасный. В настоящем обзоре литературы авторы проанализировали данные современных исследований, в том числе мультицентровых рандомизированных.

Ключевые слова: гемосорбция, гемодиализ, гемофильтрация, плазмаферез, низкомолекулярные гепарины, гепарин.
с. 119 - 125 оригинального издания
Список литературы
  1. Воинов, В. А. Мембранный плазмаферез: рекомендации для врачей / В. А. Воинов. – Москва, 2004.
  2. Davies, H. Anticoagulation in CRRT: agents and strategies in Australian ICUs / H. Davies, G. Leslie // Aust. Crit. Care. – 2007. – Vol. 20, N 1. – P. 15-26.
  3. Continuous veno-venous hemodiafiltration in children after cardiac surgery / A. Jander [et al.] // Eur. J. Cardiothorac. Surg. – 2007. – Vol. 31, N 6. – P. 1022-1028.
  4. Influence of different heparin concentrations on the results of in vitro investigations in plasmaseparation technology using capillary membrane filters / J. K. Unger [et al.] // Artif. Organs. – 2003. – Vol. 27, N 7. – P. 649-657.
  5. Hosokawa, S. Optimization of heparinization in clinical double filtration plasmapheresis / S. Hosokawa, A. Oyamaguchi, O. Yoshida // Int. J. Artif. Organs. – 1989. – Vol. 12, N 8. – P. 544-548.
  6. Amanzadeh, J. Anticoagulation and continuous renal replacement therapy / J. Amanzadeh, R. F. Jr. Reilly // Semin. Dial. – 2006. – Vol. 19, N 4. – P. 311-316.
  7. Tejedor, Alonso M. A Thrombocytopenia and anaphylaxis secondary to heparin in a hemodialysis patient / Alonso M. A. Tejedor // Clin. Nephrol. – 2005. – Vol. 63, N 3. – P. 236-240.
  8. Sulodexide for hemodialysis anticoagulation in heparin-induced thrombocytopenia type II / J. Borawski [et al.] // J. Nephrol. – 2007. – Vol. 20, N 3. – P. 370-372.
  9. Optimal anticoagulation strategy in haemodialysis with heparin-coated polyacrylonitrile membrane / S. Lavaud [et al.] // Nephrol. Dial. Transplant. – 2003. – Vol. 18, N 10. – P. 2097-2104.
  10. Berbece, A. N. Sustained low-efficiency dialysis in the ICU: cost, anticoagulation, and solute removal / A. N. Berbece, R. M. Richardson // Kidney Int. – 2006. – Vol. 70, N 5. – P. 963-968.
  11. Iloprost for additional anticoagulation in continuous renal replacement therapy - a pilot study / J. Birnbaum [et al.] // Ren. Fail. – 2007. – Vol. 29, N 3. – P. 271-277.
  12. Antithrombin supplementation for anticoagulation during continuous hemofiltration in critically ill patients with septic shock: a case-control study / D. du Cheyron [et al.] // Crit. Care. – 2006. – Vol. 10, N 2. – P. R45.
  13. Role of prostacyclin (epoprostenol) as anticoagulant in continuous renal replacement therapies: efficacy, security and cost analysis / F. J. Gainza [et al.] // J. Nephrol. – 2006. – Vol. 19, N 5. – P. 648-655.
  14. Hosokawa, S. Clinical evaluation of nafamstat mesilate (FUT 175). A new anticoagulant for plasmapheresis / S. Hosokawa, A. Oyamaguchi, O. Yoshida // ASAIO J. – 1992. – Vol. 38, N 1. – P. 59-60.
  15. Effect of anticoagulant on biocompatibility in membrane plasmapheresis / S. Omokawa [et al.] // Int. J. Artif. Organs. – 1990. – Vol. 13, N 11. – P. 768-777.
  16. Is regional citrate superior to systemic heparin anticoagulation for continuous renal replacement therapy? A prospective observational study in an adult regional critical care system / S. M. Bagshaw [et al.] // J. Crit. Care. – 2005. – Vol. 20, N 2. – P. 155-161.
  17. Citrate anticoagulation during CVVH in high risk bleeding patients / L. Cubattoli [et al.] // Int. J. Artif. Organs. – 2007. – Vol. 30, N 3. – P. 244-252.
  18. A practical citrate anticoagulation continuous venovenous hemodiafiltration protocol for metabolic control and high solute clearance / A. J. Tolwani [et al.] // Clin. J. Am. Soc. Nephrol. – 2006. – Vol. 1, N 1. – P. 79-87.
  19. Multi-centre evaluation of anticoagulation in patients receiving continuous renal replacement therapy (CRRT) / P. D. Brophy [et al.] // Nephrol. Dial. Transplant. – 2005. – Vol. 20, N 7. – P. 1416-1421.
  20. Improving the delivery of continuous renal replacement therapy using regional citrate anticoagulation / R. Swartz [et al.] // Clin. Nephrol. – 2004. – Vol. 61, N 2. – P. 134-143.
  21. Comparative analysis of procoagulatory activity of haemodialysis, haemofiltration and haemodiafiltration with a polysulfone membrane (APS) and with different modes of enoxaparin anticoagulation / R. Klingel [et al.] // Nephrol. Dial. Transplant. – 2004. – Vol. 19, N 1. – P. 164-170.
  22. Al-Arrayed, S. Use of low molecular weight heparin for hemodialysis: a short-term study / S. Al-Arrayed, R. Seshadri // Saudi J. Kidney Dis. Transpl. – 2002. – Vol. 13, N 2. – P. 146-150.
  23. Safety and efficacy of single bolus anticoagulation with enoxaparin for chronic hemodialysis. Results of an open-label post-certification study / R. Klingel [et al.] // Kidney Blood Press Res. – 2004. – Vol. 27, N 4. – P. 211-217.
  24. Naumnik, B. Unfractionated Heparin but Not Enoxaparin Causes Delayed Plasma PAI-1 Depletion in Hemodialysis Patients: A Prospective Study / B. Naumnik, K. Pawlak, M. Mysliwiec // Clin. Appl. Thromb. Hemost. – 2007. – Sept. 25.
  25. Enoxaparin but not unfractionated heparin causes a dose-dependent increase in plasma TGF-beta 1 during haemodialysis: a cross-over study / B. Naumnik [et al.] // Nephrol. Dial. Transplant. – 2007. – Vol. 22, N 6. – P. 1690-1696.
  26. The pharmacokinetics of enoxaparin do not correlate with its pharmacodynamic effect in patients receiving dialysis therapies / D. F. Brophy [et al.] // J. Clin. Pharmacol. – 2006. – Vol. 46, N 8. – P. 887-894.
  27. The initial experience of using fraxiparin in extracorporeal detoxication in clinical cardiology / Iu. N. Sirenko [et al.] // Klin. Khir. – 1994. – N 12. – P. 23-25.
  28. Anticoagulation with low-molecular-weight heparin (dalteparin) in plasmapheresis therapy: initial experience / H. Schinzel [et al.] // Transfusion. – 2006. – Vol. 46, N 4. – P. 624-629.
  29. Pharmacokinetics of the low molecular weight heparin enoxaparin during 48 h after bolus administration as an anticoagulant in haemodialysis / B. Guillet [et al.] // Nephrol. Dial. Transplant. – 2003. – Vol. 18, N 11. – P. 2348-2353.
  30. Schneiter, S. Bleeding complication due to accumulation of low-molecular-weight heparin in a patient with renal insufficiency / S. Schneiter, U. Huynh-Do, M. Heizmann // Schweiz. Rundsch. Med. Prax. – 2007. – Vol. 96, N 18. – P. 733-737.
  31. Comparison of effects of different heparins on thrombin activatable fibrinolysis inhibitor in hemodialyzed patients / J. MaByszko [et al.] // Am. J. Nephrol. – 2004. – Vol. 24, N 6. – P. 624-629.
  32. Comparison of low-molecular-weight heparin (enoxaparin sodium) and standard unfractionated heparin for haemodialysis anticoagulation / D. Saltissi [et al.] // Nephrol. Dial. Transplant. – 1999. – Vol. 14, N 11. – P. 2698-2703.
  33. Sabloff, M. The effect of plasmapheresis on the serum activity level of dalteparin: a case report / M. Sabloff, P. S. Wells // Blood Coagul. Fibrinolysis. – 2000. – Vol. 11, N 4. – P. 395-400.
  34. In vitro and in vivo evaluation of enoxaparin removal by continuous renal replacement therapies with acrylonitrile and polysulfone membranes / A. Isla [et al.] // Clin. Ther. – 2005. – Vol. 27, N 9. – P. 1444-1451.
Адрес для корреспонденции:
230017, Республика Беларусь, г. Гродно, Бульвар Ленинского Комсамола (БЛК), строение 52, УОЗ «Гродненская областная клиническая больница»
Якубцевич Р.Э.
Контакты | ©Витебский государственный медицинский университет, 2007